TABLE 7.
Changes in RNA expression levels of biofilm formation-related genes in 11 clinical isolates with radezolid or linezolid treatment.
| Biofilm formation-related genes | ||||||||||||||||
| agg | ahrC | asa1 | atn | cylA | eep | ebpA | epaI | epaOX | esp | fsrA | gelE | hyl | relA | relQ | srtA | |
| 16C1 | ||||||||||||||||
| RZD | 0.578 | 0.108a | 0.784 | 1.358 | 0.388c | – | 0.864 | 0.897 | 1.062 | 0.113d | 1.234 | 0.687 | 1.657 | 0.218f | 0.359 | 0.687 |
| LZD | 0.864 | 0.368 | 0.895 | 1.295 | 0.664 | – | 1.234 | 1.065 | 1.364 | 0.268 | 1.498 | 0.892 | 1.552 | 0.458 | 0.487 | 0.734 |
| 16C35 | ||||||||||||||||
| RZD | 0.854 | 0.169b | 1.285 | 1.069 | 0.295 | 0.965 | 0.937 | 1.298 | 1.118 | 0.165d | 0.931 | 0.885 | – | 0.311f | 0.365 | 1.058 |
| LZD | 1.068 | 0.293 | 1.154 | 1.035 | 0.431 | 1.262 | 1.364 | 1.105 | 0.997 | 0.378 | 0.854 | 1.158 | – | 0.524 | 0.487 | 1.364 |
| 16C51 | ||||||||||||||||
| RZD | 0.814 | 0.167 | 1.025 | 1.168 | 0.505 | – | 1.035 | 0.954 | 1.548 | 0.075d | 0.875 | – | – | 0.309f | 0.224 | 0.564 |
| LZD | 0.962 | 0.208 | 1.132 | 0.864 | 0.598 | – | 1.125 | 1.264 | 1.068 | 0.119 | 0.965 | – | – | 0.524 | 0.368 | 0.635 |
| 16C102 | ||||||||||||||||
| RZD | – | 0.263b | – | 0.864 | – | 0.597 | 0.824 | 0.954 | 0.931 | 0.138d | 0.768 | 0.687 | – | 0.269f | 0.218h | 0.694 |
| LZD | – | 0.597 | – | 1.126 | – | 0.854 | 0.789 | 1.158 | 0.865 | 0.367 | 0.895 | 0.885 | – | 0.486 | 0.531 | 0.954 |
| 16C124 | ||||||||||||||||
| RZD | – | 0.597 | 1.164 | 1.106 | 0.167c | 0.364 | 0.764 | 0.854 | 0.954 | 0.107e | 0.964 | 0.989 | – | 0.208 | 0.497 | 1.065 |
| LZD | – | 0.631 | 0.965 | 1.357 | 0.284 | 0.543 | 0.805 | 0.762 | 1.035 | 0.485 | 1.165 | 1.164 | – | 0.294 | 0.551 | 1.321 |
| 16C138 | ||||||||||||||||
| RZD | – | 0.156 | 0.881 | 1.265 | 0.464 | – | 1.068 | 0.924 | 1.268 | 0.255d | 1.123 | – | – | 0.368f | 0.305h | 1.246 |
| LZD | – | 0.198 | 1.098 | 1.067 | 0.657 | – | 1.267 | 1.157 | 0.954 | 0.495 | 1.065 | – | – | 0.542 | 0.687 | 1.098 |
| 16C152 | ||||||||||||||||
| RZD | 0.954 | 0.468 | 1.065 | 1.196 | 0.365c | 1.354 | 0.854 | 1.094 | 1.354 | 0.073e | 0.882 | 0.724 | – | 0.097g | 0.267h | 0.769 |
| LZD | 1.367 | 0.598 | 1.298 | 0.932 | 0.697 | 1.158 | 1.063 | 1.265 | 1.165 | 0.396 | 0.854 | 0.658 | – | 0.264 | 0.576 | 0.854 |
| 16C166 | ||||||||||||||||
| RZD | – | 0.097b | 0.854 | 1.267 | – | 0.862 | 0.962 | 1.164 | 1.264 | – | 0.931 | – | – | 0.168f | 0.186h | 0.367 |
| LZD | – | 0.167 | 0.801 | 1.065 | – | 1.065 | 1.264 | 0.938 | 1.129 | – | 1.095 | – | – | 0.291 | 0.367 | 0.431 |
| 16C201 | ||||||||||||||||
| RZD | – | 0.157b | 0.652 | 0.597 | – | – | 0.531 | 0.789 | 0.631 | – | 0.934 | – | – | 0.103g | 0.158 | 0.687 |
| LZD | – | 0.269 | 0.896 | 0.786 | – | – | 0.764 | 0.894 | 0.835 | – | 1.264 | – | – | 0.324 | 0.263 | 1.357 |
| 16C289 | ||||||||||||||||
| RZD | 0.764 | 0.298 | 1.068 | 1.267 | 0.368c | 0.714 | 0.965 | 1.158 | 0.958 | 0.085e | 0.867 | 0.534 | 2.674 | 0.208f | 0.296h | 0.974 |
| LZD | 0.878 | 0.367 | 1.165 | 1.152 | 0.587 | 1.257 | 1.247 | 1.036 | 1.168 | 0.298 | 0.906 | 0.738 | 1.687 | 0.593 | 0.687 | 1.265 |
| 16C353 | ||||||||||||||||
| RZD | – | 0.394 | 1.267 | 0.954 | 0.464 | – | 0.854 | 0.964 | 1.068 | 0.069e | 0.768 | – | – | 0.082g | 0.158i | 0.875 |
| LZD | – | 0.485 | 1.597 | 1.264 | 0.568 | – | 0.834 | 1.167 | 0.915 | 0.468 | 0.934 | – | – | 0.368 | 0.497 | 1.068 |
RZD, radezolid; LZD, linezolid. Radezolid and linezolid were used at 1/4× their minimum inhibitory concentrations (MICs). The RNA levels were detected by RT-qPCR, with untreated isolate as the reference strain (mRNA level = 1.0). −, not detected. aahrC: RZD vs. LZD, P < 0.01; bahrC: RZD vs. LZD, P < 0.05; ccylA: RZD vs. LZD, P < 0.05; desp: RZD vs. LZD, P < 0.05; eesp: RZD vs. LZD, P < 0.01; frelA: RZD vs. LZD, P < 0.05; grelA: RZD vs. LZD, P < 0.01; hrelQ: RZD vs. LZD, P < 0.05; irelQ: RZD vs. LZD, P < 0.01.